600129.SH
太极集团
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 14.21
−5.71%Aug 25, 2026, 09:41 UTC
Taiji Group announced its 2026 half-year results: net profit attributable to shareholders was 87.8573 million yuan, down 36.70% year-on-year.
Source:Aug 10, 2026, 09:02 UTC
Taiji Group's controlling subsidiary Southwest Pharmaceutical received a drug registration certificate from the National Medical Products Administration for butorphanol tartrate injection, in specifications of 1ml:1mg and 2ml:4mg, for the treatment of cancer pain and postoperative pain.
Source:Jul 20, 2026, 09:40 UTC
Taiji Group announced that Chairman Yu Min resigned and nominated Cai Maisong as a director candidate.
Source: